Pharmaceutical perspectives of cancer therapeutics: Current therapeutic uses of monoclonal antibodies

Michael D. Axelson, David E. Gerber

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Few cancer therapies have attracted the level of interest given to monoclonal antibodies. These drugs, first approved for cancer treatment in the late 1990s, provide unprecedented target specificity. In so doing, they have begun to fulfill the concept put forth by Paul Ehrlich over 100 years earlier-a magic bullet that kills cancer, but does not harm normal tissues [1]. The production of monoclonal antibodies has captured the public's awe and appreciation. The hybridoma technique, which entails the fusion of mouse and human cells into antibody factories, exemplifies the clinical benefits of biologic research. Perhaps most importantly, monoclonal antibodies offer the promise of effective cancer treatment, without the toxicities associated with conventional chemotherapy.

Original languageEnglish (US)
Title of host publicationPharmaceutical Perspectives of Cancer Therapeutics
PublisherSpringer US
Pages321-363
Number of pages43
ISBN (Print)9781441901309
DOIs
StatePublished - 2009

Fingerprint

Therapeutic Uses
Oncology
Monoclonal Antibodies
Pharmaceutical Preparations
Neoplasms
Chemotherapy
Magic
Toxicity
Industrial plants
Hybridomas
Fusion reactions
Therapeutics
Cells
Tissue
Antibodies
Drug Therapy
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pharmaceutical perspectives of cancer therapeutics : Current therapeutic uses of monoclonal antibodies. / Axelson, Michael D.; Gerber, David E.

Pharmaceutical Perspectives of Cancer Therapeutics. Springer US, 2009. p. 321-363.

Research output: Chapter in Book/Report/Conference proceedingChapter

Axelson, Michael D. ; Gerber, David E. / Pharmaceutical perspectives of cancer therapeutics : Current therapeutic uses of monoclonal antibodies. Pharmaceutical Perspectives of Cancer Therapeutics. Springer US, 2009. pp. 321-363
@inbook{c3afbc15ebb44e528b62498f2d5d6ea4,
title = "Pharmaceutical perspectives of cancer therapeutics: Current therapeutic uses of monoclonal antibodies",
abstract = "Few cancer therapies have attracted the level of interest given to monoclonal antibodies. These drugs, first approved for cancer treatment in the late 1990s, provide unprecedented target specificity. In so doing, they have begun to fulfill the concept put forth by Paul Ehrlich over 100 years earlier-a magic bullet that kills cancer, but does not harm normal tissues [1]. The production of monoclonal antibodies has captured the public's awe and appreciation. The hybridoma technique, which entails the fusion of mouse and human cells into antibody factories, exemplifies the clinical benefits of biologic research. Perhaps most importantly, monoclonal antibodies offer the promise of effective cancer treatment, without the toxicities associated with conventional chemotherapy.",
author = "Axelson, {Michael D.} and Gerber, {David E.}",
year = "2009",
doi = "10.1007/978-1-4419-0131-6_11",
language = "English (US)",
isbn = "9781441901309",
pages = "321--363",
booktitle = "Pharmaceutical Perspectives of Cancer Therapeutics",
publisher = "Springer US",

}

TY - CHAP

T1 - Pharmaceutical perspectives of cancer therapeutics

T2 - Current therapeutic uses of monoclonal antibodies

AU - Axelson, Michael D.

AU - Gerber, David E.

PY - 2009

Y1 - 2009

N2 - Few cancer therapies have attracted the level of interest given to monoclonal antibodies. These drugs, first approved for cancer treatment in the late 1990s, provide unprecedented target specificity. In so doing, they have begun to fulfill the concept put forth by Paul Ehrlich over 100 years earlier-a magic bullet that kills cancer, but does not harm normal tissues [1]. The production of monoclonal antibodies has captured the public's awe and appreciation. The hybridoma technique, which entails the fusion of mouse and human cells into antibody factories, exemplifies the clinical benefits of biologic research. Perhaps most importantly, monoclonal antibodies offer the promise of effective cancer treatment, without the toxicities associated with conventional chemotherapy.

AB - Few cancer therapies have attracted the level of interest given to monoclonal antibodies. These drugs, first approved for cancer treatment in the late 1990s, provide unprecedented target specificity. In so doing, they have begun to fulfill the concept put forth by Paul Ehrlich over 100 years earlier-a magic bullet that kills cancer, but does not harm normal tissues [1]. The production of monoclonal antibodies has captured the public's awe and appreciation. The hybridoma technique, which entails the fusion of mouse and human cells into antibody factories, exemplifies the clinical benefits of biologic research. Perhaps most importantly, monoclonal antibodies offer the promise of effective cancer treatment, without the toxicities associated with conventional chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84900273516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900273516&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0131-6_11

DO - 10.1007/978-1-4419-0131-6_11

M3 - Chapter

AN - SCOPUS:84900273516

SN - 9781441901309

SP - 321

EP - 363

BT - Pharmaceutical Perspectives of Cancer Therapeutics

PB - Springer US

ER -